Successes achieved and challenges ahead in translating biomarkers into clinical applications

AAPS Journal

Volumn 12, Issue 3, 2010, Pages 243-253

  Tesch, Greg ^a   Amur, Shashi ^b   Schousboe, John T ^c,d   Siegel, Jeffrey N ^e   Lesko, Lawrence J ^f   Bai, Jane P F ^f  

^a MONASH MEDICAL CENTRE   (Australia)

^b OTS   (United States)

^c PARK NICOLLET INSTITUTE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e CDER   (United States)

^f OTS   (United States)

Author keywords

biomarkers; bone; diabetic nephropathy; drug development; genetic; inflammation; osteoporosis; proteomics; rheumatoid arthritis

Indexed keywords

ABACAVIR; ABATACEPT; ADALIMUMAB; ALENDRONIC ACID; ALPHA FETOPROTEIN; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MARAVIROC; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; RITUXIMAB; SALAZOSULFAPYRIDINE; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR 1; UNINDEXED DRUG; URIC ACID; BIOLOGICAL MARKER;

ANTIVIRAL ACTIVITY; BONE TURNOVER; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOMICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CANCER; LOW DRUG DOSE; MEDICAL RESEARCH; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOLYSIS; OSTEOPOROSIS; PATIENT SELECTION; PHARMACOGENOMICS; PREDICTION; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; DIABETIC NEPHROPATHIES; DRUG DESIGN; FRACTURES, BONE; GENETIC PREDISPOSITION; GENETICS;

ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BONE RESORPTION; DIABETIC NEPHROPATHIES; DRUG DESIGN; FRACTURES, BONE; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 77955973604     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-010-9182-4     Document Type: Review

References (74)

1. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html.
2. Innovation or stagnation? Critical path opportunities report. http://www.fda.gov/oc/initiatives/criticalpath/reports/opp-report.pdf.
3. Innovation or stagnation? Critical path opportunities list. http://www.fda.gov/oc/initiatives/criticalpath/reports/opp-list.pdf.
4. Guidance for industry, pharmacogenomic data submissions. http://www.fda.gov/cber/gdlns/pharmdtasub.pdf.
5. MS Orr F Goodsaid S Amur A Rudman FW Frueh 2007 The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program Clin Pharmacol Ther 81 2 294 7 10.1038/sj.clpt.6100053 17259954 1:STN:280:DC%2BD2s%2FlsFerug%3D%3D
6. F Goodsaid F Frueh 2007 Biomarker qualification pilot process at the US Food and Drug Administration Aaps J 9 1 E105 8 10.1208/aapsj0901010 17408233 1:CAS:528:DC%2BD2sXksFGktrg%3D
7. FDA and EMEA conclude that new renal safety biomarkers are qualified for specific regulatory purposes. http://www.c-path.org/pdf/PSTC-nephro-VXDS- summary-final.pdf.
8. Approved label of Maraviroc. http://www.fda.gov/cder/foi/label/2007/ 022128lbl.pdf.
9. Approved label of Trastuzumab. http://www.fda.gov/cder/foi/label/2002/ trasgen082802LB.pdf.
10. Approved label of azathioprine. http://www.fda.gov/cder/foi/label/2005/ 016324s030 slp.
11. AR Hughes WR Spreen M Mosteller, et al. 2008 Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility Pharmacogenomics J 8 6 365 74 10.1038/tpj.2008.3 18332899 1:CAS:528:DC%2BD1cXhtlOjtr3M
12. S Mallal E Phillips G Carosi, et al. 2008 HLA-B5701 screening for hypersensitivity to abacavir N Engl J Med 358 6 568 79 10.1056/NEJMoa0706135 18256392
13. LJ Waters S Mandalia B Gazzard M Nelson 2007 Prospective HLA-B5701 screening and abacavir hypersensitivity: a single centre experience Aids 21 18 2533 4 10.1097/QAD.0b013e328273bc07 18025891 1:CAS:528:DC%2BD2sXhtlWjtL3I
14. S Rodriguez-Novoa P Garcia-Gasco F Blanco, et al. 2007 Value of the HLA-B5701 allele to predict abacavir hypersensitivity in Spaniards AIDS Res Hum Retroviruses 23 11 1374 6 10.1089/aid.2006.0244 18184080 1:CAS:528: DC%2BD1cXlsVeqtw%3D%3D
15. ME el-Houseini MS Mohammed WM Elshemey TD Hussein OS Desouky AA Elsayed 2005 Enhanced detection of hepatocellular carcinoma Cancer Control 12 4 248 53 16258497
16. KC Fang 2007 Clinical utilities of peripheral blood gene expression profiling in the management of cardiac transplant patients J Immunotoxicol 4 3 209 17 10.1080/15476910701385570 18958730 1:CAS:528:DC%2BD2sXhtFGqtLzK
17. WD Comper G Jerums TM Osicka 2004 Differences in urinary albumin detected by four immunoassays and high-performance liquid chromatography Clin Biochem 37 2 105 11 10.1016/j.clinbiochem.2003.10.008 14725940 1:CAS:528: DC%2BD2cXjtFChsQ%3D%3D
18. A Shaikh JC Seegmiller TM Borland, et al. 2008 Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin Clin Chem 54 9 1504 10 10.1373/clinchem.2008.107508 18617580 1:CAS:528:DC%2BD1cXhtVGqsbzF
19. AD Rule 2007 Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease Curr Opin Nephrol Hypertens 16 3 242 9 10.1097/MNH.0b013e328057de8b 17420668 1:CAS:528:DC%2BD2sXlsFWnt7k%3D
20. M Mussap M Dalla Vestra P Fioretto, et al. 2002 Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients Kidney Int 61 4 1453 61 10.1046/j.1523-1755.2002.00253.x 11918752 1:CAS:528:DC%2BD38XjtVGqtLw%3D
21. ET Rosolowsky MA Niewczas LH Ficociello BA Perkins JH Warram AS Krolewski 2008 Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy Diabetes Res Clin Pract 82 Suppl 1 S46 53 10.1016/j.diabres.2008.09.018 18849087 1:CAS:528:DC%2BD1cXhtlGhurjL
22. T Narita M Hosoba M Kakei S Ito 2006 Increased urinary excretions of immunoglobulin G, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes Diabetes Care 29 1 142 4 10.2337/diacare.29.01.06.dc05-1063 16373913 1:CAS:528:DC%2BD28Xps1ajsg%3D%3D
23. A Patari C Forsblom M Havana H Taipale PH Groop H Holthofer 2003 Nephrinuria in diabetic nephropathy of type 1 diabetes Diabetes 52 12 2969 74 10.2337/diabetes.52.12.2969 14633858
24. MM van Timmeren MC van den Heuvel V Bailly SJ Bakker H van Goor CA Stegeman 2007 Tubular kidney injury molecule-1 (KIM-1) in human renal disease J Pathol 212 2 209 17 10.1002/path.2175 17471468 1:CAS:528:DC%2BD2sXnt1GktLo%3D
25. PP Wolkow MA Niewczas B Perkins, et al. 2008 Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics J Am Soc Nephrol 19 4 789 97 10.1681/ASN.2007050556 18256362 1:CAS:528: DC%2BD1cXkvFOhtro%3D
26. GH Tesch 2008 MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy Am J Physiol Renal Physiol 294 4 F697 701 10.1152/ajprenal.00016.2008 18272603 1:CAS:528: DC%2BD1cXkvVyktrc%3D
27. SW Ha HJ Kim JS Bae, et al. 2004 Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy Diabetes Res Clin Pract 65 2 167 73 10.1016/j.diabres.2004.01. 007 15223229 1:CAS:528:DC%2BD2cXlt1Wht7g%3D
28. H Dihazi GA Muller S Lindner, et al. 2007 Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients Clin Chem 53 9 1636 45 10.1373/clinchem.2007.088260 17634209 1:CAS:528:DC%2BD2sXhtVSgu7fL
29. HH Otu H Can D Spentzos, et al. 2007 Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy Diabetes Care 30 3 638 43 10.2337/dc06-1656 17327333 1:CAS:528: DC%2BD2sXjs1Grtbs%3D
30. K Rossing H Mischak M Dakna, et al. 2008 Urinary proteomics in diabetes and CKD J Am Soc Nephrol 19 7 1283 90 10.1681/ASN.2007091025 18448586 1:CAS:528:DC%2BD1cXovFeksrY%3D
31. BA Perkins LH Ficociello KH Silva DM Finkelstein JH Warram AS Krolewski 2003 Regression of microalbuminuria in type 1 diabetes N Engl J Med 348 23 2285 93 10.1056/NEJMoa021835 12788992 1:CAS:528:DC%2BD3sXkt1Kktrk%3D
32. WD Comper LM Hilliard DJ Nikolic-Paterson LM Russo 2008 Disease-dependent mechanisms of albuminuria Am J Physiol Renal Physiol 295 6 F1589 600 10.1152/ajprenal.00142.2008 18579704 1:CAS:528:DC%2BD1cXhsFSnur%2FN
33. M Essawy O Soylemezoglu EC Muchaneta Kubara J Shortland CB Brown AM el Nahas 1997 Myofibroblasts and the progression of diabetic nephropathy Nephrol Dial Transplant 12 1 43 50 10.1093/ndt/12.1.43 9027772 1:STN:280: DyaK2s7nvFGitA%3D%3D
34. BI Freedman M Bostrom P Daeihagh DW Bowden 2007 Genetic factors in diabetic nephropathy Clin J Am Soc Nephrol 2 6 1306 16 10.2215/CJN.02560607 17942768 1:CAS:528:DC%2BD2sXhtlGgtr7O
35. JR Schelling HE Abboud SB Nicholas, et al. 2008 Genome-wide scan for estimated glomerular filtration rate in multi-ethnic diabetic populations: the Family Investigation of Nephropathy and Diabetes (FIND) Diabetes 57 1 235 43 10.2337/db07-0313 18003762 1:CAS:528:DC%2BD1cXmt1Wquw%3D%3D
36. JJ Rogus GD Poznik MG Pezzolesi, et al. 2008 High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach Diabetes 57 9 2519 26 10.2337/db07-1086 18559660 1:CAS:528:DC%2BD1cXhtFSrtrbM
37. C Granier K Makni L Molina B Jardin-Watelet H Ayadi F Jarraya 2008 Gene and protein markers of diabetic nephropathy Nephrol Dial Transplant 23 3 792 9 10.1093/ndt/gfm834 18065784 1:CAS:528:DC%2BD1cXivVOru7s%3D
38. KG Saag GG Teng NM Patkar, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 6 762 84 10.1002/art.23721 18512708 1:CAS:528:DC%2BD1cXot1Wgs74%3D
39. AH van der Helm-van Mil L Padyukov RE Toes L Klareskog TW Huizinga 2008 Genome-wide single-nucleotide polymorphism studies in rheumatology: hype or hope? Arthritis Rheum 58 9 2591 7 10.1002/art.23751 18759298
40. PG Conaghan MA Quinn P O'Connor RJ Wakefield Z Karim P Emery 2002 Can very high-dose anti-tumor necrosis factor blockade at onset of rheumatoid arthritis produce long-term remission? Arthritis Rheum 46 7 1971 2 10.1002/art.10274 12124886 author reply 1973
41. ND Nguyen HG Ahlborg JR Center JA Eisman TV Nguyen 2007 Residual lifetime risk of fractures in women and men J Bone Miner Res 22 6 781 8 10.1359/jbmr.070315 17352657
42. SL Silverman ME Minshall W Shen KD Harper S Xie 2001 The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study Arthritis Rheum 44 11 2611 9 10.1002/1529- 0131(200111)44:11<2611::AID-ART441>3.0.CO;2-N 11710717 1:STN:280:DC%2BD3MnmsFeqsg%3D%3D
43. R Burge B Dawson-Hughes DH Solomon JB Wong A King A Tosteson 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 3 465 75 10.1359/jbmr.061113 17144789
44. C MacLean S Newberry M Maglione, et al. 2008 Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis Ann Intern Med 148 3 197 213 18087050
45. HK Datta WF Ng JA Walker SP Tuck SS Varanasi 2008 The cell biology of bone metabolism J Clin Pathol 61 5 577 87 10.1136/jcp.2007.048868 18441154 1:CAS:528:DC%2BD1cXmvVyks78%3D
46. Seibel MJ, Eastell R, Gundberg CM, Hannon R, Pols HAP. Biochemical markers of bone metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic; 2002. p. 1543-71.
47. Robins SPBJ, Bilezikian J. Collagen cross-linking and metabolism. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of bone biology. San Diego: Academic; 2002. p. 211-24.
48. M Wichers E Schmidt F Bidlingmaier D Klingmuller 1999 Diurnal rhythm of CrossLaps in human serum Clin Chem 45 10 1858 60 10508135 1:CAS:528: DyaK1MXms1aisb0%3D
49. A Claudon P Vergnaud C Valverde A Mayr U Klause P Garnero 2008 New automated multiplex assay for bone turnover markers in osteoporosis Clin Chem 54 9 1554 63 10.1373/clinchem.2008.105866 18676587 1:CAS:528:DC%2BD1cXhtVGqsb3K
50. R Eastell RA Hannon 2008 Biomarkers of bone health and osteoporosis risk Proc Nutr Soc 67 2 157 62 10.1017/S002966510800699X 18412989
51. M Samoszuk M Leuther N Hoyle 2008 Role of serum P1NP measurement for monitoring treatment response in osteoporosis Biomarkers Med 2 5 495 508 10.2217/17520363.2.5.495 1:CAS:528:DC%2BD1cXhtlKmtLfO
52. JA Clowes HC Allen DM Prentis R Eastell A Blumsohn 2003 Octreotide abolishes the acute decrease in bone turnover in response to oral glucose J Clin Endocrinol Metab 88 10 4867 73 10.1210/jc.2002-021447 14557467 1:CAS:528:DC%2BD3sXoslemtbc%3D
53. SJ Glover P Garnero K Naylor A Rogers R Eastell 2008 Establishing a reference range for bone turnover markers in young, healthy women Bone 42 4 623 30 10.1016/j.bone.2007.12.218 18289953 1:CAS:528:DC%2BD1cXjs1Whur0%3D
54. KJ Obrant KK Ivaska P Gerdhem SL Alatalo K Pettersson HK Vaananen 2005 Biochemical markers of bone turnover are influenced by recently sustained fracture Bone 36 5 786 92 10.1016/j.bone.2005.02.009 15804493 1:CAS:528:DC%2BD2MXjvVOisLg%3D
55. S Adami D Gatti O Viapiana, et al. 2008 Physical activity and bone turnover markers: a cross-sectional and a longitudinal study Calcif Tissue Int 83 6 388 92 10.1007/s00223-008-9184-8 18949504 1:CAS:528:DC%2BD1cXhsVCnurbN
56. M Inoue H Tanaka T Moriwake M Oka C Sekiguchi Y Seino 2000 Altered biochemical markers of bone turnover in humans during 120 days of bed rest Bone 26 3 281 6 10.1016/S8756-3282(99)00282-3 10710002 1:CAS:528:DC%2BD3cXhtFals74%3D
57. P Ardissone E Rota L Durelli P Limone GC Isaia 2002 Effects of high doses of corticosteroids on bone metabolism J Endocrinol Invest 25 2 129 33 11929083 1:CAS:528:DC%2BD38XjtFSqtbo%3D
58. RD Chapurlat P Garnero E Sornay-Rendu ME Arlot B Claustrat PD Delmas 2000 Longitudinal study of bone loss in pre- and perimenopausal women: evidence for bone loss in perimenopausal women Osteoporos Int 11 6 493 8 10.1007/ s001980070091 10982164 1:STN:280:DC%2BD3cvotFSiuw%3D%3D
59. J Lenora KK Ivaska KJ Obrant P Gerdhem 2007 Prediction of bone loss using biochemical markers of bone turnover Osteoporos Int 18 9 1297 305 10.1007/s00198-007-0379-z 17440674 1:STN:280:DC%2BD2svptFajuw%3D%3D
60. P Garnero E Hausherr MC Chapuy, et al. 1996 Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study J Bone Miner Res 11 10 1531 8 10.1002/jbmr.5650111021 8889854 1:STN:280: DyaK2s%2FksVOrsQ%3D%3D
61. P Garnero E Sornay-Rendu B Claustrat PD Delmas 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study J Bone Miner Res 15 8 1526 36 10.1359/jbmr.2000.15.8.1526 10934651 1:CAS:528:DC%2BD3cXlvVSjtrg%3D
62. P Gerdhem KK Ivaska A Isaksson, et al. 2007 Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women J Bone Miner Res 22 1 127 34 10.1359/jbmr.061003 17032146 1:CAS:528: DC%2BD2sXhtVWnuro%3D
63. MC Hochberg S Greenspan RD Wasnich P Miller DE Thompson PD Ross 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J Clin Endocrinol Metab 87 4 1586 92 10.1210/jc.87.4.1586 11932287 1:CAS:528:DC%2BD38XivFKlt7k%3D
64. RD Chapurlat L Palermo P Ramsay SR Cummings 2005 Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial Osteoporos Int 16 7 842 8 10.1007/s00198-004-1770-7 15580479 1:CAS:528:DC%2BD2MXls1ahurs%3D
65. SL Greenspan RA Parker L Ferguson HN Rosen L Maitland-Ramsey DB Karpf 1998 Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial J Bone Miner Res 13 9 1431 8 10.1359/jbmr.1998.13.9.1431 9738515 1:CAS:528:DyaK1cXmtVCjsrg%3D
66. P Ravn D Hosking D Thompson, et al. 1999 Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study J Clin Endocrinol Metab 84 7 2363 8 10.1210/jc.84.7.2363 10404804 1:CAS:528:DyaK1MXks1agtb8%3D
67. DC Bauer P Garnero JP Bilezikian, et al. 2006 Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis J Clin Endocrinol Metab 91 4 1370 5 10.1210/jc.2005-1712 16449339 1:CAS:528:DC%2BD28XjvFOksb0%3D
68. R Eastell I Barton RA Hannon A Chines P Garnero PD Delmas 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J Bone Miner Res 18 6 1051 6 10.1359/jbmr.2003.18.6.1051 12817758 1:CAS:528:DC%2BD3sXkslOhsb0%3D
69. DC Bauer P Garnero MC Hochberg, et al. 2006 Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial J Bone Miner Res 21 2 292 9 10.1359/JBMR.051018 16418785 1:CAS:528:DC%2BD28Xhs1Kmu7Y%3D
70. MJ Seibel V Naganathan I Barton A Grauer 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J Bone Miner Res 19 2 323 9 10.1359/JBMR.0301231 14969403 1:CAS:528:DC%2BD2cXhs1elsrs%3D
71. PD Delmas AA Licata JY Reginster, et al. 2006 Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover Bone 39 2 237 43 10.1016/j.bone.2006.02.003 16563890 1:CAS:528: DC%2BD28Xls1ejt70%3D
72. P Chen JH Satterwhite AA Licata, et al. 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis J Bone Miner Res 20 6 962 70 10.1359/JBMR.050105 15883636 1:CAS:528:DC%2BD2MXlsFehtr0%3D
73. P Kothawala E Badamgarav S Ryu RM Miller RJ Halbert 2007 Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis Mayo Clin Proc 82 12 1493 501 10.4065/82.12.1493 18053457
74. PD Delmas B Vrijens R Eastell, et al. 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 4 1296 304 10.1210/jc.2006-1526 17244788 1:CAS:528:DC%2BD2sXksVSrsbc%3D